RT Journal Article
SR Electronic
T1 Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3729
DO 10.1183/13993003.congress-2021.PA3729
VO 58
IS suppl 65
A1 Frank Kanniess
A1 Lilla Tamasi
A1 Robert R. Mroz
A1 Petros Bakakos
A1 Susanne Tubis
A1 Gustavo Resler Plat
A1 Anat Shavit
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3729.abstract
AB Background: Despite advances in the field of biologic therapies, clinical management of severe asthma still represents an unmet need.Aims and objectives: The aim of the study was to generate real-world data on the characteristics of severe asthma patients and their eligibility for biologics.Methods: In this cross-sectional study, patient characteristics and patient-reported outcomes were collected from severe asthma patients at a single study visit in primary and secondary care settings in Europe. Investigators were asked to share their judgement on the patients’ eligibility for biologics and their suitability for referral to specialized care for further clinical assessment.Results: Between 04/2018 and 07/2020, 1025 severe asthma patients were assessed in 12 European countries. The investigator’s specialty differed by region (99% vs 22% specialists in Eastern vs Western Europe) due to different healthcare systems.Most patients were female (69%) and diagnosed at adult age (median 42 years). Median eosinophil counts were 300 cells/µl, IgE levels 158 UI/ml and FeNO 29.5 ppb. Over the previous year, 25% received long-term oral corticosteroid therapy (≥50% of year), 69% received short-course systemic corticosteroids (>3 days) and 78% had exacerbations. Asthma control was poor (mean ACQ-6 score 2.6, 95% CI 2.5–2.6).Per clinical judgement, 75% were considered eligible for biologics; 62% were eligible per label criteria. Label criteria were in agreement with the investigators’ judgement in Western Europe. Moreover, 66% were candidates for referral to specialists in Western Europe.Conclusions: In this study, the majority of severe asthma patients were eligible for biologics, highlighting the current shortcomings in the management of severe asthma.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3729.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).